TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials.

Lee, Dae-Won; Jang, Myoung-Jin; Lee, Kyung-Hun; Cho, Eun Ju; Lee, Jeong-Hoon; Yu, Su Jong; Kim, Yoon Jun; Yoon, Jung-Hwan; Kim, Tae-Yong; Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Kim, Tae-You
British journal of cancer
2016Nov ; 115 ( 10 ) :1201-1205.
저자 상세정보
Lee, Dae-Won -
Jang, Myoung-Jin -
Lee, Kyung-Hun -
Cho, Eun Ju -
Lee, Jeong-Hoon -
Yu, Su Jong -
Kim, Yoon Jun -
Yoon, Jung-Hwan -
Kim, Tae-Yong -
Han, Sae-Won -
Oh, Do-Youn -
Im, Seock-Ah -
Kim, Tae-You -
ABSTRACT
BACKGROUND: Time to progression (TTP) is suggested as a reliable endpoint compared with the progression-free survival in the clinical trials of hepatocellular carcinoma (HCC). However, the correlation between TTP and overall survival (OS) has never been studied.

METHODS: We searched PubMed and Embase data to obtain data source. Eligible studies were randomised controlled phase III trials, which evaluated the efficacy of systemic chemotherapy or molecular targeted therapy in advanced HCC. The association of treatment effects as shown by the hazard ratio (HR) of TTP and OS in each trial was assessed by the Spearman rank correlation coefficient (r(s)) and linear regression analysis. The association between median TTP and OS was also investigated.

RESULTS: Nine studies with a total of 18 treatment arms and 6318 patients were included. Incremental benefit from the study treatment in TTP from each trial was correlated with incremental benefit in OS. The r(s) value and R(2) value between log (HR(TTP)) and log (HR(OS)) was 0.73 (95% confidence interval (CI) 0.12-0.94, P=0.024) and 0.57. The minimum TTP effect to predict a treatment effect on OS was 0.63. Median TTP was associated with median OS. The r(s) value between TTP and OS was 0.73 (95% CI 0.40-0.89, P<0.001) and the corresponding R(2) was 0.42.

CONCLUSIONS: Our study results suggest that TTP could be used as a surrogate marker for OS in the clinical trials of advanced HCC. However, the results suggest modest correlation between treatment effects on TTP and OS.
hepatocellular carcinoma, time to progression, overall survival, chemotherapy, surrogate marker
MESH
Antineoplastic Agents/*therapeutic use, Biomarkers/*metabolism, Carcinoma, Hepatocellular/*drug therapy/metabolism/mortality, Clinical Trials, Phase III as Topic, Disease Progression, Disease-Free Survival, Humans, Liver Neoplasms/*drug therapy/metabolism/mortality, Molecular Targeted Therapy/methods, Proportional Hazards Models, Randomized Controlled Trials as Topic, Regression Analysis, Statistics, Nonparametric, Treatment Outcome
링크

주제코드
주제명(Target field)
연구대상(Population)
연구참여(Sample size)
대상성별(Gender)
질병특성(Condition Category)
연구환경(Setting)
연구설계(Study Design)
연구기간(Period)
중재방법(Intervention Type)
중재명칭(Intervention Name)
키워드(Keyword)
유효성결과(Recomendation)
TTP could be used as a surrogate marker for OS in the clinical trials of advanced HCC.
연구비지원(Fund Source)
근거수준평가(Evidence Hierarchy)
출판년도(Year)
참여저자수(Authors)
대표저자
DOI
KCD코드
ICD 03
건강보험코드